Search results for "Cutaneous"

showing 10 items of 1022 documents

Keratoacanthoma Centrifugum Marginatum (KCM) after photodynamic therapy with good response to oral retinoids and topical 5‐fluorouracil

2019

Keratoacanthoma centrifugum marginatum (KCM) is a rare variant of keratoacanthoma (KA), characterized by progressive peripheral growth, and usually devoid of deep invasion. Different systemic (oral retinoids) or topical treatments have been reported, but there is not a well-defined therapeutic protocol. We report the case of a KCM developing after photodynamic therapy (PDT) on the right leg of a 64-year-old woman. It was treated successfully with oral acitretin combined with topical 5-Fluorouracil + salicylic acid for 5 months. This is the first case of KCM developing after PDT and successfully treated with oral retinoid combined with topical treatment.

Keratoacanthomamedicine.medical_specialtymedicine.medical_treatmentAdministration OralTopical treatmentPhotodynamic therapyDermatologyAdministration CutaneousAcitretinRetinoids030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseDermatologyAcitretinKeratoacanthomaTreatment OutcomePhotochemotherapyFluorouracil030220 oncology & carcinogenesisFemaleDermatologic AgentsFluorouracilbusinessOral retinoidmedicine.drugDermatologic Therapy
researchProduct

Regional hypothermia of the kidney: surface or transarterial perfusion cooling? A functional study.

1980

Hypothermia reduces ischemic damage if prolonged occlusion of the renal artery is required during an in situ kidney operation. Hypothermia may be achieved by external cooling or by transarterial hypothermic perfusion. External cooling may lower intrarenal temperature heterogeneously. Perfusion techniques via intra-arterial catheters introduced percutaneously are associated with minimal technical difficulties. The 95 patients who underwent extensive hypothermic nephrolithotomy had differential 131iodine hippuran clearance studies preoperatively, and 2 weeks and 6 to 46 months postoperatively. Sixty-three kidneys were cooled by transarterial hypothermic perfusion and 39 were cooled with topic…

Kidneymedicine.medical_specialtyPercutaneousbusiness.industryUrologyRenal functionHypothermic perfusionHypothermiaKidneyRenal Artery ObstructionSurgeryKidney Calculimedicine.anatomical_structureHypothermia InducedAnesthesiamedicine.arteryOcclusionmedicineHumansInfusions Intra-Arterialmedicine.symptomRenal arterybusinessPerfusionThe Journal of urology
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Leishmania major-infected murine Langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against exper…

2000

Leishmania major-infected C57BL / 6 skin-dendritic cells (DC) are activated and release cytokines (including IL-12 p70), and likely initiate protective Th1 immunity in vivo (von Stebut, E. et al., J. Exp. Med.188: 1547 – 1552). To characterize differences in DC function in mice that are genetically susceptible (BALB / c) and resistant (C57BL / 6) to cutaneous leishmaniasis, we analyzed the effects of L. major on Langerhans cell-like, fetal skin-derived DC (FSDDC) from both strains. BALB / c- and C57BL / 6-FSDDC ingested similar numbers of amastigotes, but did not ingest metacyclic promastigotes. Like C57BL / 6-FSDDC, infection of BALB / c-FSDDC led to up-regulation of MHC class I and II ant…

Langerhans cellImmunologyDendritic cellBiologymedicine.diseaseLeishmaniabiology.organism_classificationVirologyImmune systemmedicine.anatomical_structureAntigenCutaneous leishmaniasisInterleukin 12medicineImmunology and AllergyLeishmania majorEuropean Journal of Immunology
researchProduct

Induction of Regulatory T Cells in Leishmania major‒Infected BALB/c Mice Does Not Require Langerin+ Dendritic Cells

2021

Langerhans cellLangerinRegulatory T cellLeishmaniasis CutaneousDermatologyT-Lymphocytes RegulatoryBiochemistryBALB/cMicemedicineAnimalsHumansLectins C-TypeLeishmania majorLymphocyte CountMolecular BiologyLeishmania majorSkinMice Inbred BALB CbiologyCell BiologyDendritic cellbiology.organism_classificationMolecular biologySpecific Pathogen-Free OrganismsDisease Models AnimalMannose-Binding Lectinsmedicine.anatomical_structureLangerhans CellsAntigens Surfacebiology.proteinJournal of Investigative Dermatology
researchProduct

Langerhans cells are negative regulators of the anti-Leishmania response

2011

Langerhans cells suppress the immune response to low-dose Leishmania major infection in part by inducing regulatory T cells.

LangerinT cellImmunologyPriming (immunology)Leishmaniasis Cutaneouschemical and pharmacologic phenomenaT-Lymphocytes RegulatoryImmune toleranceInterferon-gammaMiceImmune systemSDG 3 - Good Health and Well-beingparasitic diseasesmedicineImmune ToleranceImmunology and AllergyAnimalsInterferon gammaLeishmania majorLeishmaniasis VaccinesLeishmania majorbiologyintegumentary systemBrief Definitive ReportFOXP3hemic and immune systemsbiochemical phenomena metabolism and nutritionTh1 Cellsbiology.organism_classificationDisease Models Animalmedicine.anatomical_structureLangerhans CellsImmunologybiology.proteinmedicine.drug
researchProduct

Giant subcutaneous lipomatosis in Myoclonic Epilepsy with Ragged Red Fibers syndrome: The first literature report of “laparoscopic” excision

2020

Background MERRF (Myoclonic Epilepsy with Ragged Red Fibers) is a rare multisystem clinical disorder due to a pathogenic variant of the mitochondrial DNA. Rare symptoms of MERRF include multiple systemic lipomatosis with symmetric uncapsulated lipomas occurs generally on the posterior cervical region and upper back. Methods We report the clinical case of a 46 years-old Caucasian man with MERRF syndrome who presented with MSL on the right cervical region. We decided to perform a mini-invasive approach using laparoscopic instruments. We performed a 10-mm incision about 5 cm under the mass and conducted a blunt dissection of the subcutaneous plane. Then we positioned a 10-mm port and started C…

Laparoscopic surgerymedicine.medical_specialtySubcutaneous lipomatosisbusiness.industryMERRF syndromemedicine.medical_treatmentLipomatosisMini-invasive surgeryMERRF syndromelcsh:Surgerylcsh:RD1-811Laparoscopic excisionLaparoscopic surgerymedicine.diseaseSurgeryMini invasive surgerySettore MED/18 - Chirurgia GeneraleRagged-red fibersSubcutaneous lipomatosismedicineMyoclonic epilepsySurgeryVideoassisted surgerybusiness
researchProduct

Remote Photoplethysmography for Evaluation of Cutaneous Sensory Nerve Fiber Function

2021

About 2% of the world’s population suffers from small nerve fiber dysfunction, neuropathy, which can result in severe pain. This condition is caused by damage to the small nerve fibers and its assessment is challenging, due to the lack of simple and objective diagnostic techniques. The present study aimed to develop a contactless photoplethysmography system using simple instrumentation, for objective and non-invasive assessment of small cutaneous sensory nerve fiber function. The approach is based on the use of contactless photoplethysmography for the characterization of skin flowmotions and topical heating evoked vasomotor responses. The feasibility of the technique was evaluated on volunt…

Laser Doppler ImagingPopulationSensationNerve fiber030204 cardiovascular system & hematologylcsh:Chemical technologyBiochemistryArticleAnalytical Chemistry03 medical and health sciencesNerve Fibers0302 clinical medicineremote photoplethysmographyPhotoplethysmogrampain assessmentHumansMedicinelcsh:TP1-1185Electrical and Electronic EngineeringPhotoplethysmographyeducationInstrumentationSkinneuropathic paineducation.field_of_studyVasomotorbusiness.industryCutaneous nervecutaneous perfusioncutaneous flowmotionstopical heatingAtomic and Molecular Physics and OpticsCutaneous sensory nervemedicine.anatomical_structureNeuropathic painvasomotor responsechronic painbusiness030217 neurology & neurosurgeryBiomedical engineeringSensors
researchProduct

Penile Abflußvenenokklusion: Vergleich von erektiler Funktion und Kavernosometrie vor und nach perkutanen Eingriffen

1993

After percutaneous transpenile or retrograde venous occlusion for the treatment of a cavernous leak, the clinical results were correlated with cavernosometric flow measurements in 27 patients. In 15 patients, venous occlusion led to a reduction of the maintenance flow: in patients who showed improvement there was an average reduction of 30 ml/min, in those without improvement or deterioration it averaged 0.3 or 13 ml/min respectively. In 7 patients there was increased flow (up to +21 ml/min). One of these patients showed improved erectile function; the remaining 6 showed no change as was also the case in 5 other patients who had no change in cavernosometric measurements. Our findings sugges…

LeakPapaverinemedicine.medical_specialtyPercutaneousbusiness.industrymedicine.diseaseSurgerymedicine.anatomical_structureErectile dysfunctionPhentolamineAnesthesiaOcclusionmedicineRadiology Nuclear Medicine and imagingVeinbusinessPenismedicine.drugRöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren
researchProduct

Answer to “Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas”

2017

Leiomyosarcoma0301 basic medicineLeiomyosarcomaPathologymedicine.medical_specialtySkin Neoplasmsbusiness.industryLeishmaniasis CutaneousGeneral Medicinemedicine.diseasePathology and Forensic Medicine03 medical and health sciences030104 developmental biology0302 clinical medicineRecurrence030220 oncology & carcinogenesismedicineHumansTumor Suppressor Protein p53businessAnnals of Diagnostic Pathology
researchProduct